These patients also were less likely to be hospitalized for any reason or need a nerve block to ease their pain, results showed
Still, they will work best as one part of a whole-person, whole-picture approach alongside lifestyle change and other integrative support
Hair loss concerns are less documented with retatrutide than with some other GLP-1 agonists, but the rapid weight loss itself can trigger telogen effluvium, a temporary shedding condition
Obesity and adipose tissue research Type 2 diabetes and insulin resistance Knee osteoarthritis Obstructive sleep apnea Non-alcoholic steatohepatitis (NASH) Key Findings from the Literature 01Phase 2: 24.2% mean weight loss at 48 weeks at highest dose 02Phase 3 TRIUMPH-4: 28.7% mean weight loss at 68 weeks 03Highest weight loss efficacy of any obesity pharmacotherapy in clinical trials to date 04Glucagon receptor agonism adds hepatic lipolysis absent from GLP-1-only agents 1 Independent third-party lab reports for this peptide
This has not been studied but represents a practical approach some clinicians explore
However, it is important to disclose all medications you are taking to your healthcare provider, as empagliflozin can interact with other drugs
